Zacks Research Comments on HealthEquity, Inc.’s Q2 2025 Earnings (NASDAQ:HQY)

HealthEquity, Inc. (NASDAQ:HQY) – Equities research analysts at Zacks Research issued their Q2 2025 earnings per share estimates for shares of HealthEquity in a note issued to investors on Monday, June 24th. Zacks Research analyst R. Department expects that the company will earn $0.51 per share for the quarter. The consensus estimate for HealthEquity’s current full-year earnings is $2.12 per share. Zacks Research also issued estimates for HealthEquity’s Q3 2025 earnings at $0.52 EPS, Q4 2025 earnings at $0.54 EPS, FY2025 earnings at $2.11 EPS, Q1 2026 earnings at $0.74 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.71 EPS, FY2026 earnings at $2.75 EPS, Q1 2027 earnings at $0.83 EPS and FY2027 earnings at $3.50 EPS.

Several other equities analysts have also recently issued reports on the company. Robert W. Baird lifted their price objective on HealthEquity from $98.00 to $104.00 and gave the stock an “outperform” rating in a report on Tuesday, June 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $92.00 price objective on shares of HealthEquity in a research note on Tuesday, June 4th. BTIG Research lifted their target price on shares of HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. JPMorgan Chase & Co. increased their price target on shares of HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Finally, Raymond James lifted their price objective on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Friday, June 7th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $101.67.

HealthEquity Stock Performance

Shares of HQY stock opened at $86.20 on Thursday. The company has a market cap of $7.50 billion, a price-to-earnings ratio of 93.70, a price-to-earnings-growth ratio of 1.40 and a beta of 0.55. The stock has a 50 day simple moving average of $81.03 and a 200-day simple moving average of $78.04. HealthEquity has a 12-month low of $61.32 and a 12-month high of $87.72. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.44.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Monday, June 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.08. The business had revenue of $287.60 million during the quarter, compared to the consensus estimate of $278.78 million. HealthEquity had a return on equity of 7.77% and a net margin of 7.71%.

Institutional Trading of HealthEquity

Hedge funds and other institutional investors have recently modified their holdings of the business. Farallon Capital Management LLC acquired a new position in HealthEquity in the first quarter worth about $229,000. Hancock Whitney Corp acquired a new position in HealthEquity in the first quarter worth about $1,073,000. Grandeur Peak Global Advisors LLC grew its stake in HealthEquity by 2,377.1% in the first quarter. Grandeur Peak Global Advisors LLC now owns 58,980 shares of the company’s stock worth $4,815,000 after purchasing an additional 56,599 shares in the last quarter. Janus Henderson Group PLC grew its stake in HealthEquity by 1.1% in the first quarter. Janus Henderson Group PLC now owns 1,100,715 shares of the company’s stock worth $89,851,000 after purchasing an additional 12,448 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in HealthEquity by 7.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 51,384 shares of the company’s stock worth $4,195,000 after purchasing an additional 3,365 shares in the last quarter. 99.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Vice Chairman Stephen Neeleman sold 2,080 shares of the firm’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $85.01, for a total value of $176,820.80. Following the transaction, the insider now directly owns 90,515 shares of the company’s stock, valued at $7,694,680.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Jon Kessler sold 32,326 shares of HealthEquity stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $82.83, for a total transaction of $2,677,562.58. Following the sale, the chief executive officer now directly owns 232,176 shares of the company’s stock, valued at $19,231,138.08. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Vice Chairman Stephen Neeleman sold 2,080 shares of HealthEquity stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $85.01, for a total value of $176,820.80. Following the sale, the insider now directly owns 90,515 shares in the company, valued at $7,694,680.15. The disclosure for this sale can be found here. Insiders have sold 34,806 shares of company stock valued at $2,888,383 over the last three months. 2.20% of the stock is owned by company insiders.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.